Suppr超能文献

晚期心力衰竭与终末期心力衰竭:二者是否存在差异?

Advanced Heart Failure and End-Stage Heart Failure: Does a Difference Exist.

作者信息

Severino Paolo, Mather Paul J, Pucci Mariateresa, D'Amato Andrea, Mariani Marco Valerio, Infusino Fabio, Birtolo Lucia Ilaria, Maestrini Viviana, Mancone Massimo, Fedele Francesco

机构信息

Department of Cardiovascular, Respiratory, Nephrology, Anesthesiology and Geriatric Sciences, Sapienza University of Rome, Viale del Policlinico 155, 00161 Rome, Italy.

Department of Medicine, Division of Cardiology University of Pennsylvania, Perelman School of Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104, USA.

出版信息

Diagnostics (Basel). 2019 Nov 1;9(4):170. doi: 10.3390/diagnostics9040170.

Abstract

Advanced heart failure (AdHF) represents a challenging aspect of heart failure patients. Because of worsening clinical symptoms, high rates of re-hospitalization and mortality, AdHF represents an unstable condition where standard treatments are inadequate and additional interventions must be applied. A heart transplant is considered the optimal therapy for AdHF, but the great problem linked to the scarcity of organs and long waiting lists have led to the use of mechanical circulatory support with ventricular-assist device (VAD) as a destination therapy. VAD placement improves the prognosis, functional status, and quality of life of AdHF patients, with high rates of survival at 1 year, similar to transplant. However, the key element is to select the right patient at the right moment. The complete assessment must include a careful clinical evaluation, but also take into account psychosocial factors that are of crucial importance in the out-of-hospital management. It is important to distinguish between AdHF and end-stage HF, for which advanced therapy interventions would be unreasonable due to severe and irreversible organ damage and, instead, palliative care should be preferred to improve quality of life and relief of suffering. The correct selection of patients represents a great issue to solve, both ethically and economically.

摘要

晚期心力衰竭(AdHF)是心力衰竭患者面临的一个具有挑战性的方面。由于临床症状不断恶化、再住院率和死亡率高,AdHF代表了一种不稳定状态,在这种状态下,标准治疗方法并不充分,必须采取额外的干预措施。心脏移植被认为是治疗AdHF的最佳疗法,但与器官短缺和漫长的等待名单相关的重大问题导致使用心室辅助装置(VAD)进行机械循环支持作为一种终末治疗方法。植入VAD可改善AdHF患者的预后、功能状态和生活质量,1年生存率较高,与移植相似。然而,关键因素是在正确的时间选择合适的患者。全面评估必须包括仔细的临床评估,同时还要考虑到在院外管理中至关重要的社会心理因素。区分AdHF和终末期心力衰竭很重要,对于终末期心力衰竭,由于严重且不可逆的器官损害,进行高级治疗干预是不合理的,相反,应优先选择姑息治疗以提高生活质量和减轻痛苦患者的正确选择是一个在伦理和经济方面都亟待解决的重大问题。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5230/6963179/6eaaa69dc86a/diagnostics-09-00170-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验